Theriva Biologics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 22
- Market Cap
- -
- Website
- http://www.therivabio.com
- Introduction
Theriva Biologics, Inc.(formerly Synthetic Biologics, Inc.) is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infection...
Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05045833
- Locations
- 🇺🇸
Spaulding Clinical Research LLC, West Bend, Wisconsin, United States
Pharmacokinetics, Safety, and Tolerability of SYN-020
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04815993
- Locations
- 🇺🇸
Spaulding Clinical Research LLC, West Bend, Wisconsin, United States
SYN-004 Safety and Tolerability in Allo-HCT Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04692181
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT02563106
- Locations
- 🇷🇴
Synthetic Biologics Investigational SIte, Bucharest, Romania
🇵🇱SyntheticBiologics Investigational Site, Tychy, Poland
🇷🇸Synthetic Biologics Investigational Site, Čačak, Serbia
A Study of the Effect of SYN-010 on Subjects With IBS-C
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT02495623
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02493036
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02473640
- Locations
- 🇨🇦
Synthetic Biologics Investigative Site, Montreal, Canada
A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Theriva Biologics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02419001